Partnership website: https://www.cbe.europa.eu/
The objective of the initiative is to produce major contributions to the climate targets by 2030, pave the way for climate neutrality by 2050, and increase sustainability and circularity of production and consumption systems in line with the European Green Deal.
It aims to develop and expand the sustainable sourcing and conversion of biomass into bio-based products focusing on multiscale biorefinery processing and apply circular economy approaches such as utilisation of biological waste from agriculture, industry and municipal sectors. It also aims to deploy bio-based innovation at regional scale with the view to revival of rural and marginal regions.
The partnership was established by the Council regulation (EU) 2021/2085 of 19 November 2021
Contact
Commission services: Marton Keri
Partners: Biobased Industries Consortium (BIC) Dirk Carrez, Partnership website
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.